(Reuters) – Eli Lilly said on Friday it was extending the deadline for its tender offer for Point Biopharma shares to Dec. 1, from Nov. 16 previously.
In October, Lilly agreed to acquire the company in an all-cash deal valued at $1.4 billion.
(Reporting by Sriparna Roy in Bengaluru)
